Attached files

file filename
10-Q - FORM 10-Q FOR THE PERIOD ENDED JANUARY 31, 2011 - TENAX THERAPEUTICS, INC.oxbt_10q.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - TENAX THERAPEUTICS, INC.oxbt_ex311.htm
EX-10.4 - MASTER AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex104.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - TENAX THERAPEUTICS, INC.oxbt_ex321.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - TENAX THERAPEUTICS, INC.oxbt_ex312.htm
EX-10.6 - LEASE AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex106.htm
EX-10.5 - AMENDMENT NO. 1 TO MASTER AGREEMENT - TENAX THERAPEUTICS, INC.oxbt_ex105.htm
Exhibit 32.2
 
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Oxygen Biotherapeutics, Inc. (the “Company”) on Form 10-Q for the period ended January 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael B. Jebsen, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: March 21, 2011
By:
 /s/ Michael B. Jebsen  
    Michael B. Jebsen  
   
(Chief  Financial Officer)
 
       
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.